How We Unified a Pharma CDMO’s Brand Post-Acquisition and Grew Organic Traffic 222%

After an acquisition left their digital presence fragmented, this contract development and manufacturing organization needed a single, clear brand identity online. Here is how we built it and what the numbers looked like six months later.

When a pharmaceutical CDMO acquires another company, the science and operations side usually gets immediate attention. The brand, the website, and the search visibility? Those tend to sit in limbo. That is exactly what happened with this client. Two companies became one on paper, but online they still looked and sounded like two separate businesses, each with its own website, its own messaging, and its own inconsistent Google footprint. We helped them fix that.

Why Brand Unification After an Acquisition Should Be a Growth Priority

If your company has gone through a merger or acquisition, you already know the operational headaches that follow. But the digital side creates a different kind of problem: buyers and procurement teams researching your company find conflicting information, outdated pages, and two brands competing against each other in search results. That confusion costs you leads. In the CDMO space, where contract decisions involve long evaluation cycles and deep due diligence, a scattered online presence signals instability. Prospects move on.

Brand unification is not just a design exercise. It is a growth strategy. When done well, it consolidates your search authority, clarifies your value proposition, and gives your sales team a single story to tell.

Five takeaways from this client story:

• Two websites, one problem: Duplicate domains after an acquisition split your search authority and confuse potential buyers
• Messaging consistency drives trust: CDMO buyers expect clear positioning across every page and platform they evaluate
• Technical SEO compounds fast: Redirect mapping, canonical tags, and site architecture decisions made early prevent months of lost traffic
• Content strategy fills the sales funnel: Service-level pages targeting specific drug development stages brought in qualified organic traffic
• 222% organic growth in under a year: A unified brand backed by a smart content plan outperformed both legacy sites combined

Who Was the Client?

The client is a mid-market pharmaceutical CDMO operating in the Southeast United States with capabilities spanning formulation development, analytical testing, and commercial-scale manufacturing. They serve both emerging biotech firms and established pharmaceutical companies, handling everything from early-stage development through FDA-ready production. Before the acquisition, they had a solid reputation in the industry but almost no digital presence to match it.

What Was Holding Them Back?

The acquisition closed nine months before the client came to us, and the digital side had barely been touched. Two separate websites were live, each with different branding, different messaging, and different domain authority. Neither site ranked well on its own because they were cannibalizing each other in search results for the same service terms.

The acquired company’s website was outdated, built on a rigid platform with no content management flexibility. The parent company’s site was slightly newer but still lacked service-detail pages, had no blog or resource section, and carried thin meta data across the board. Google Business Profiles for both entities were incomplete. Neither site had structured data markup. Internal teams were sending prospects to whichever URL they remembered, creating an inconsistent experience from the first click.

The core issue was simple to name but hard to fix: two digital identities existed where only one should.

How Did We Approach the Brand and SEO Rebuild?

We started with a full audit of both domains, crawling every page, cataloging backlinks, and mapping which URLs carried the most search equity. That audit shaped every decision that followed.

Choosing the Right Domain and Redirect Strategy

The parent company’s domain had stronger backlink authority and more indexed pages, so we kept it as the primary domain. We built a detailed 301 redirect map for every page on the acquired company’s site, preserving link equity and making sure no bookmarked or externally linked page returned a 404 error. We also set up canonical tags across the new site to prevent any remaining duplicate content issues.

Rebuilding the Site on WordPress

We rebuilt the website on WordPress, giving the internal team a platform they could actually manage going forward. The new site architecture reflected the combined company’s full capabilities, with dedicated service pages for each stage of the drug development lifecycle: formulation, analytical services, stability testing, clinical supply, and commercial manufacturing. Each page targeted specific long-tail keywords that procurement teams and R&D directors use when evaluating CDMOs.

Unifying the Brand Voice and Visual Identity

We developed a single brand voice guide that blended the credibility of the parent company with the specialized expertise the acquired firm was known for. New messaging positioned the combined organization as a full-service CDMO partner rather than two separate vendors stitched together. We carried that voice across the website, Google Business Profile, LinkedIn, and all downloadable resources like capability decks and spec sheets.

“Post-acquisition branding is not about picking a winner between two companies. It is about building something stronger than either one was alone. The digital experience has to reflect that from day one, because that is where your next client starts their evaluation.” – Strategy Team at Emulent Marketing

Building a Content Engine for Organic Growth

With the site architecture in place, we launched a content strategy targeting high-intent informational queries in the CDMO space. We published detailed guides on topics like selecting a CDMO for Phase I clinical trials, understanding cGMP compliance requirements, and comparing outsourced vs. in-house analytical testing. Each piece was designed to attract decision-makers already in a research phase and move them toward a capabilities conversation.

We also created a resource hub with downloadable content gated behind simple contact forms, giving the sales team a steady flow of qualified leads tied directly to organic search traffic.

What Were the Results?

222% increase in organic traffic within 10 months of launch.

That number represents the combined site’s performance compared to the total traffic both legacy sites were generating before the project began. Other results worth noting:

14 service pages ranking on page one for targeted CDMO and pharmaceutical manufacturing keywords within six months of going live.

3.4x increase in organic lead form submissions compared to the combined baseline from both previous websites.

Zero traffic lost from the acquired domain. The redirect strategy preserved 98% of the referring link equity, and the acquired company’s branded search terms now resolve cleanly to the unified site.

Google Business Profile views up 187% after consolidation, verification, and regular posting.

Average session duration increased 41%, indicating that visitors were engaging with the deeper, more detailed service content.

What Can Other Pharmaceutical and Life Sciences Companies Learn from This?

Acquisitions in the pharmaceutical and biotech space are only accelerating. PE-backed roll-ups, strategic acquisitions of niche capabilities, and international expansions are reshaping the CDMO market every quarter. Yet most of these deals treat the digital brand as an afterthought, something to “get to later.”

That delay has a real cost. Every month two competing domains sit live, you are splitting your search authority and sending mixed signals to Google and to your prospects. Every month without a unified content strategy is a month your competitors are capturing the organic traffic you should own.

“In the CDMO space, your website is your first sales meeting. If it looks like two companies taped together, that is exactly how prospects will judge your operations.” – Strategy Team at Emulent Marketing

The companies getting this right are the ones treating brand unification as a strategic investment, not an administrative task. They are mapping redirects before the acquisition closes. They are auditing both domains in parallel with operational due diligence. And they are building content strategies that reflect the combined company’s strengths from the first day the new site goes live.

Ready to Strengthen Your Pharmaceutical Brand Online?

If your company has gone through an acquisition, merger, or rebrand and your digital presence still reflects the old reality, that gap is costing you visibility and leads. The Emulent team works with pharmaceutical and life sciences companies to build unified brands backed by search strategies that drive real pipeline growth. Reach out to the Emulent Team to talk about your brand development and SEO strategy.